🇺🇸 FDA

Intelligence · Clinical Pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs
676

Quick answer

Neurology & CNS: NovaPharmaNews indexes 676 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Page 7 of 15

  1. GlyT-1 inhibitor-1

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  2. Green Tea Polyphenols (EGCG/ECG)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  3. Iloperidone

    Vanda Pharmaceuticals Netherlands B.V.

    Parkinson Disease Psychosis

    phase 2 small molecule terminated

    1 trial

  4. Iloperidone crystalline formulation

    Vanda Pharmaceuticals Netherlands B.V.

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  5. Insulin

    United Therapeutics Europe Ltd

    Multiple Sclerosis, Relapsing-Remitting

    phase 2 small molecule completed

    1 trial

  6. K0706

    Advanced Accelerator Applications

    Early Parkinson Disease

    phase 2 small molecule terminated

    1 trial

  7. KALINOX 50%/50%, gaz medicinal comprime, Medical Air

    Tour Hekla

    psychiatry

    phase 2 small molecule active

    1 trial

  8. KYV-101

    Kyverna Therapeutics

    Multiple Sclerosis, Primary Progressive

    phase 2 mab active

    1 trial

  9. Kesimpta 20 mg solution for injection in pre-filled pen, Ocrevus 300 mg concentrate for solution for infusion, MabThera 500 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, MabThera 100 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, Kesimpta 20 mg solution for injection in pre-filled syringe, Ocrevus 300 mg concentrate for solution for infusion, MabThe

    Kyverna Therapeutics

    Primary or Secondary Progressive Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  10. Ketamine Hydrochloride

    BRIGHT MINDS BIOSCIENCES INC.

    Depression

    phase 2 small molecule completed

    1 trial

  11. LX1001

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 mab completed

    1 trial

  12. LY2140023

    Novo Nordisk A/S

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  13. Lamivudina Aurovitas 300 mg comprimidos recubiertos con película EFG

    MEDA Pharma GmbH & Co. KG

    Mild Cognitive impairment due to Alzheimer Disease

    phase 2 small molecule active

    1 trial

  14. Laquinimod 0.6

    Teva Pharma GmbH

    Relapsing Multiple Sclerosis

    phase 2 small molecule terminated

    1 trial

  15. Leuprolide acetate

    Voyager Therapeutics

    Alzheimer Disease

    phase 2 small molecule completed

    2 trials

  16. Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction treatment for patients aged 18 to 60 (up to 65 for phase II) with a newly diagnosed Primary Central Nervous System Lymphoma

    The George Institute

    Primary Central Nervous System Lymphoma (PCNSL)

    phase 2 other active

    1 trial

  17. Low Dose GT-02287

    Gain Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  18. Lu AA34893

    H. Lundbeck A/S

    Depression in Patients With Bipolar Disorder

    phase 2 small molecule terminated

    1 trial

  19. Lu AE58054

    H. Lundbeck A/S

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  20. Luvadaxistat

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule completed

    2 trials

  21. MINOCIN 100 mg capsule rigide

    Zafatek

    Depression

    phase 2 small molecule active

    1 trial

  22. MK-1167

    Merck KGaA, Darmstadt, Germany

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  23. MK-2214

    Merck KGaA, Darmstadt, Germany

    Early Alzheimer's Disease

    phase 2 mab active

    1 trial

  24. MK-2214, Florquinitau F18, Placebo to MK-2214

    Merck Sharp and Dohme

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  25. ML-007C-MA

    MapLight Therapeutics

    Schizophrenia

    phase 2 small molecule active

    1 trial

  26. ML-007C-MA

    MapLight Therapeutics

    Psychosis Associated With Alzheimer's Disease

    phase 2 small molecule active

    2 trials

  27. MLC901

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  28. Matched Placebo for test product Frexalimab, Frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  29. Matched placebo for product, GADOBUTROL , SAR443820

    Sanofi-aventis Healthcare Pty Ltd

    Multiple sclerosis

    phase 2 small molecule active

    1 trial

  30. Matching Placebo tablets without active substance, BIIB122

    Biogen

    Parkinson's Disease

    phase 2 small molecule active

    1 trial

  31. Mebufotenin, Mebufotenin, Inhalation vapour, liquid, Mebufotenin

    Elan Pharma International

    Treatment-resistant depression (TRD)

    phase 2 small molecule active

    1 trial

  32. Melperone HCl

    Lundbeck Australia Pty Ltd

    Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  33. Mifepristone

    CORCEPT THERAPEUTICS INC

    Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  34. Mivelsiran, Placebo

    Alnylam Netherlands B.V.

    Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain, causing problems such as bleeding into the brain

    phase 2 small molecule active

    1 trial

  35. Morphine

    Hospital Authority, Hong Kong

    Respiratory Depression

    phase 2 small molecule active

    1 trial

  36. N-acetyl cysteine

    United Therapeutics Europe Ltd

    Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  37. N-acetylcysteine capsule

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  38. NBI-1117570

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule active

    1 trial

  39. NBI-1117570, NBI-1117570, Placebo for nbi-1117570

    NEUROCRINE BIOSCIENCES INC

    Schizophrenia

    phase 2 small molecule active

    1 trial

  40. NBI-5788

    NEUROCRINE BIOSCIENCES INC

    Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  41. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    2 trials

  42. NMDAE

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Prodromal Schizophrenia

    phase 2 small molecule active

    1 trial

  43. NMDAE plus AIFA

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule active

    1 trial

  44. NV-5138

    SUPERNUS PHARMACEUTICALS, INC.

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  45. NeuroEPO

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  46. NurOwn (MSC-NTF cells)

    BRAINSTORM CELL THERAPEUTICS INC.

    Multiple Sclerosis, Chronic Progressive

    phase 2 mab completed

    1 trial

  47. OPC-34712

    Otsuka Beijing Research Institute

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  48. ORY-2001 Low dose

    BRIGHT MINDS BIOSCIENCES INC.

    Mild to Moderate Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

676 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.